Cargando…

Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores

BACKGROUND: Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors have revolutionized treatment for patients with BRAF-mutated melanoma. Although left ventricular systolic dysfunction associated with these therapies has been repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glen, Claire, Adam, Sarah, McDowell, Kirsty, Waterston, Ashita, Tan, Yun Yi, Petrie, Mark C., Coats, Caroline J., Lang, Ninian N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635885/ https://www.ncbi.nlm.nih.gov/pubmed/37969652 http://dx.doi.org/10.1016/j.jaccao.2023.04.004

Ejemplares similares

Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review
por: Glen, Claire, et al.
Publicado: (2022)

Cardiotoxic effects of angiogenesis inhibitors
por: Dobbin, Stephen J.H., et al.
Publicado: (2021)

Cardiotoxicity of Contemporary Anticancer Immunotherapy
por: Dal’bo, Natalie, et al.
Publicado: (2020)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer
por: Henriksen, Peter A., et al.
Publicado: (2023)

Cellular and Molecular Mechanisms of MEK1 Inhibitor–Induced Cardiotoxicity
por: Beck, Tyler C., et al.
Publicado: (2022)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries
por: Guha, Avirup, et al.
Publicado: (2021)

Cardiotoxicity: precision medicine with imprecise definitions
por: Chung, Robin, et al.
Publicado: (2018)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities
por: Fleischmann, Jakob, et al.
Publicado: (2023)

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
por: Chen, Wenjing, et al.
Publicado: (2023)

Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
por: Sherazi, Saadia, et al.
Publicado: (2023)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment
por: Bronte, Enrico, et al.
Publicado: (2015)

Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy
por: Estep, Anne L., et al.
Publicado: (2007)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
por: Mazor, Roei D, et al.
Publicado: (2020)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
por: Winzent, Shelby, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kmhqhtmhr68rs1etlf12bm0ke6